S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
Laser breakthrough could send stock soaring 2,467% (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Laser breakthrough could send stock soaring 2,467% (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price & News

$22.01
+0.16 (+0.73%)
(As of 06/2/2023 ET)
Compare
Today's Range
$21.40
$22.15
50-Day Range
$15.31
$23.60
52-Week Range
$15.23
$24.58
Volume
418,595 shs
Average Volume
449,615 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.50

Crinetics Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
106.7% Upside
$45.50 Price Target
Short Interest
Healthy
6.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$132,624 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.41) to ($3.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

295th out of 983 stocks

Pharmaceutical Preparations Industry

133rd out of 486 stocks


CRNX stock logo

About Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Crinetics Pharmaceuticals (CRNX) Gets a Buy from Piper Sandler
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
The Latest Analyst Ratings for Crinetics Pharmaceuticals
See More Headlines

CRNX Price History

CRNX Company Calendar

Last Earnings
11/05/2021
Today
6/02/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.50
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+106.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-163,920,000.00
Net Margins
-4,090.69%
Pretax Margin
-4,090.69%

Debt

Sales & Book Value

Annual Sales
$4.74 million
Book Value
$5.19 per share

Miscellaneous

Free Float
50,838,000
Market Cap
$1.19 billion
Optionable
Not Optionable
Beta
0.94

Key Executives

  • Scott R. Struthers
    President, Chief Executive Officer & Director
  • Jeff E Knight
    Chief Operating Officer
  • Marc J. S. Wilson
    Chief Financial Officer
  • Stephen F. BetzStephen F. Betz
    Chief Scientific Officer
  • Alan Seth Krasner
    Chief Medical Officer













CRNX Stock - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price forecast for 2023?

5 brokers have issued 1 year target prices for Crinetics Pharmaceuticals' shares. Their CRNX share price forecasts range from $35.00 to $56.00. On average, they predict the company's stock price to reach $45.50 in the next year. This suggests a possible upside of 106.7% from the stock's current price.
View analysts price targets for CRNX
or view top-rated stocks among Wall Street analysts.

How have CRNX shares performed in 2023?

Crinetics Pharmaceuticals' stock was trading at $18.30 at the start of the year. Since then, CRNX stock has increased by 20.3% and is now trading at $22.01.
View the best growth stocks for 2023 here
.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,440,000 shares, a drop of 18.9% from the April 30th total of 4,240,000 shares. Based on an average daily volume of 449,500 shares, the days-to-cover ratio is presently 7.7 days.
View Crinetics Pharmaceuticals' Short Interest
.

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our CRNX earnings forecast
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its earnings results on Friday, November, 5th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.01. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 52.55% and a negative net margin of 4,090.69%.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.33%), Wellington Management Group LLP (6.73%), Perceptive Advisors LLC (6.58%), State Street Corp (4.11%), Braidwell LP (3.74%) and First Light Asset Management LLC (3.00%). Insiders that own company stock include Ajay Madan, Dana Pizzuti, Jeff E Knight, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $22.01.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.19 billion and generates $4.74 million in revenue each year. The company earns $-163,920,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

The company employs 143 workers across the globe.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.

This page (NASDAQ:CRNX) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -